US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class III · Low risk Terminated

Wal-Tussin DM

Reason Incorrect/Undeclared Excipient: Product contains alcohol

AptaPharma Inc. NDC 0363-0324-28 D-0787-2022
Class I · High risk Terminated

Pink Pussycat SENSUAL ENHANCEMENT capsule

Reason Marketed Without An Approved NDA/ANDA: FDA analysis found the product to contain undeclared sildenafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Pink Toyz D-0785-2022
Class I · High risk Terminated

IDArubicin Hydrochloride Injection USP 5gm/5mL

Reason Presence of Particulate Matter: Product was found to contain silica and iron oxide

Teva Pharmaceuticals USA Inc NDC 0703-4154-11 D-0765-2022
Class II · Moderate risk Terminated

Preferred Pharmaceuticals

Reason Out of specification results observed in dissolution during long term stability testing.

Preferred Pharmaceuticals, Inc. NDC 68788-6390-09 D-0769-2022
Class II · Moderate risk Terminated

Diclofenac Sodium Topical Solution 1.5% w/w

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Preferred Pharmaceuticals, Inc. NDC 68788-7918-01 D-0773-2022
Class II · Moderate risk Terminated

Econazole Nitrate Cream

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Preferred Pharmaceuticals, Inc. NDC 68788-7406-03 D-0771-2022
Class II · Moderate risk Terminated

Clobetasol Propionate Lotion 0.05%

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Preferred Pharmaceuticals, Inc. NDC 68788-7768-01 D-0768-2022
Class II · Moderate risk Terminated

Lansoprazole Delayed-Release Capsules

Reason Failed Dissolution Specifications; during long term stability testing.

Dr. Reddy's Laboratories, Inc. NDC 55111-399-90 D-0738-2022
Class II · Moderate risk Terminated

Lansoprazole Delayed-Release Capsules

Reason Failed Dissolution Specifications; during long term stability testing.

Dr. Reddy's Laboratories, Inc. NDC 55111-398-30 D-0737-2022
Class II · Moderate risk Terminated

Testosterone Cypionate *gs*

Reason Lack of sterility assurance.

Drug Depot, Inc., dba APS Pharmacy D-0735-2022
Class II · Moderate risk Terminated

(ca) Gonadorelin

Reason Lack of sterility assurance.

Drug Depot, Inc., dba APS Pharmacy D-0729-2022
Class II · Moderate risk Terminated

Gonadorelin

Reason Lack of sterility assurance.

Drug Depot, Inc., dba APS Pharmacy D-0728-2022
Class I · High risk Terminated

Symjepi

Reason Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

Adamis Pharmaceuticals Corporation NDC 78670-131-02 D-0764-2022
Class I · High risk Terminated

Symjepi

Reason Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

Adamis Pharmaceuticals Corporation NDC 78670-130-02 D-0763-2022
Class II · Moderate risk Terminated

Accuretic

Reason CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

Pfizer Inc. NDC 0071-5212-23 D-0761-2022
Class II · Moderate risk Terminated

quinapril HCl/hydrochlorothiazide tablets

Reason CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

Pfizer Inc. NDC 59762-0223-1 D-0760-2022
Class II · Moderate risk Terminated

quinapril HCl/hydrochlorothiazide tablets

Reason CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

Pfizer Inc. NDC 59762-0220-1 D-0759-2022
Class II · Moderate risk Terminated

quinapril and hydrochlorothiazide tablets

Reason CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

Pfizer Inc. NDC 59762-5225-9 D-0758-2022
Class II · Moderate risk Terminated

Accuretic

Reason CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

Pfizer Inc. NDC 0071-0223-23 D-0757-2022
Class II · Moderate risk Terminated

Accuretic

Reason CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

Pfizer Inc. NDC 0071-0220-23 D-0756-2022